$30.06
-2.47 (-7.59%)
Open$30.01
Previous Close$32.53
Day High$30.60
Day Low$28.53
52W High$40.65
52W Low$9.96
Volume—
Avg Volume801.5K
Market Cap1.58B
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-37.7% upside
Current
$30.06
$30.06
Target
$18.74
$18.74
$15.89
$18.74 avg
$31.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 572.13M | 572.72M | 559.98M |
| Net Income | -99,921,707 | -80,567,499 | -92,627,690 |
| Profit Margin | -17.5% | -14.1% | -16.5% |
| EBITDA | -119,066,634 | -104,548,216 | -110,415,827 |
| Free Cash Flow | -98,412,160 | -88,741,836 | -111,480,768 |
| Rev Growth | +16.0% | -4.7% | +5.4% |
| Debt/Equity | 0.49 | 0.55 | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |